Literature DB >> 23674819

Lack of use in the literature from the last 20 years supports dropping traditional schizophrenia subtypes from DSM-5 and ICD-11.

David L Braff1, James Ryan, Anthony J Rissling, William T Carpenter.   

Abstract

The diagnoses of paranoia, catatonia, and hebephrenia preceded the use of dementia praecox and Bleuler's subsequent recognition of a heterogenous "Group of Schizophrenias." With some modification, traditional schizophrenia subtypes have been formalized for many years in the Diagnostic and Statistical Manual of Mental Disorders (DSM) and International Classification of Diseases (ICD) classification systems. While widely used in the past, it is not clear that the schizophrenia subtypes remain in wide use or are influential in 21st-century research and clinical practice, and especially in the scientific literature. A review of published articles reveals over the last 20 years (1990, 2000, 2010) the use of traditional subtypes in the literature has fallen from 27.7% to 9.8% to 6.5%. Thus, by 2010, the use of subtypes in the leading literature venues declined to <10%. These facts strongly support DSM-5 and ICD-11 proposed elimination of traditional schizophrenia subtypes from a research and evolving knowledge perspective because traditional subtypes are simply no longer being used much in the scientific literature.

Entities:  

Keywords:  classification; schizophrenia; subtypes

Mesh:

Year:  2013        PMID: 23674819      PMCID: PMC3686462          DOI: 10.1093/schbul/sbt068

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  18 in total

1.  Another view of schizophrenia subtypes. A report from the international pilot study of schizophrenia.

Authors:  W T Carpenter; J J Bartko; C L Carpenter; J S Strauss
Journal:  Arch Gen Psychiatry       Date:  1976-04

2.  Human genetics. Genetic influences on disease remain hidden.

Authors:  Jocelyn Kaiser
Journal:  Science       Date:  2012-11-23       Impact factor: 47.728

3.  Subtype stability in schizophrenia.

Authors:  K S Kendler; A M Gruenberg; M T Tsuang
Journal:  Am J Psychiatry       Date:  1985-07       Impact factor: 18.112

Review 4.  A separate disease within the syndrome of schizophrenia.

Authors:  B Kirkpatrick; R W Buchanan; D E Ross; W T Carpenter
Journal:  Arch Gen Psychiatry       Date:  2001-02

Review 5.  Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder.

Authors:  David L Braff; Robert Freedman; Nicholas J Schork; Irving I Gottesman
Journal:  Schizophr Bull       Date:  2006-11-06       Impact factor: 9.306

6.  An attempted integration of information relevant to schizophrenic subtypes.

Authors:  W T Carpenter; J H Stephens
Journal:  Schizophr Bull       Date:  1979       Impact factor: 9.306

7.  The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs.

Authors:  J S Strauss; W T Carpenter; J J Bartko
Journal:  Schizophr Bull       Date:  1974       Impact factor: 9.306

Review 8.  The neuropsychiatric translational revolution: still very early and still very challenging.

Authors:  Lara Braff; David L Braff
Journal:  JAMA Psychiatry       Date:  2013-08       Impact factor: 21.596

9.  Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia.

Authors:  Joshua L Roffman; J Steven Lamberti; Eric Achtyes; Eric A Macklin; Gail C Galendez; Lisa H Raeke; Noah J Silverstein; Jordan W Smoller; Michele Hill; Donald C Goff
Journal:  JAMA Psychiatry       Date:  2013-05       Impact factor: 21.596

10.  Association analysis of 94 candidate genes and schizophrenia-related endophenotypes.

Authors:  Tiffany A Greenwood; Gregory A Light; Neal R Swerdlow; Allen D Radant; David L Braff
Journal:  PLoS One       Date:  2012-01-13       Impact factor: 3.240

View more
  14 in total

Review 1.  Inflammation and the two-hit hypothesis of schizophrenia.

Authors:  Keith A Feigenson; Alex W Kusnecov; Steven M Silverstein
Journal:  Neurosci Biobehav Rev       Date:  2013-11-15       Impact factor: 8.989

2.  Can genomics help usher schizophrenia into the age of RDoC and DSM-6?

Authors:  Ayman H Fanous
Journal:  Schizophr Bull       Date:  2015-05       Impact factor: 9.306

3.  Impact of DSM-5 changes on the diagnosis and acute treatment of schizophrenia.

Authors:  Taina Mattila; Maarten Koeter; Tamar Wohlfarth; Jitschak Storosum; Wim van den Brink; Lieuwe de Haan; Eske Derks; Hubertus Leufkens; Damiaan Denys
Journal:  Schizophr Bull       Date:  2014-12-20       Impact factor: 9.306

4.  ICD-11 symposia at the World Congress of Psychiatry.

Authors:  Gaia Sampogna
Journal:  World Psychiatry       Date:  2015-02       Impact factor: 49.548

Review 5.  [Hebephrenia - a viable psychopathological construct?]

Authors:  M Jäger; T Becker; M E Wigand
Journal:  Nervenarzt       Date:  2018-01       Impact factor: 1.214

Review 6.  Psychosis.

Authors:  David B Arciniegas
Journal:  Continuum (Minneap Minn)       Date:  2015-06

7.  Symptom rating scales for schizophrenia and other primary psychotic disorders in ICD-11.

Authors:  J W Keeley; W Gaebel
Journal:  Epidemiol Psychiatr Sci       Date:  2017-06-19       Impact factor: 6.892

Review 8.  Motor Abnormalities: From Neurodevelopmental to Neurodegenerative Through "Functional" (Neuro)Psychiatric Disorders.

Authors:  Victor Peralta; Manuel J Cuesta
Journal:  Schizophr Bull       Date:  2017-09-01       Impact factor: 9.306

9.  Identifying phenotypic signatures of neuropsychiatric disorders from electronic medical records.

Authors:  Svetlana Lyalina; Bethany Percha; Paea LePendu; Srinivasan V Iyer; Russ B Altman; Nigam H Shah
Journal:  J Am Med Inform Assoc       Date:  2013-08-16       Impact factor: 4.497

Review 10.  Lumateperone for the Treatment of Schizophrenia.

Authors:  Amber Edinoff; Natalie Wu; Charles deBoisblanc; Catherine Olivia Feltner; Mariah Norder; Vesela Tzoneva; Adam M Kaye; Elyse M Cornett; Alan D Kaye; Omar Viswanath; Ivan Urits
Journal:  Psychopharmacol Bull       Date:  2020-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.